Valuation: Intervacc AB

Market Cap 229M 22.49M 20.51M 18.96M 17.11M 32.23M 2.1B 33.5M 90.53M 1.13B 84.37M 82.6M 3.58B P/E 2026 *
-2.36x
P/E 2027 * -2.86x
Enterprise Value 149M 14.6M 13.31M 12.31M 11.11M 20.92M 1.36B 21.75M 58.77M 736M 54.77M 53.62M 2.33B EV / Sales 2026 *
7.22x
EV / Sales 2027 * 6.32x
Free-Float
82.02%
Yield 2026 *
-
Yield 2027 * -
1 day-3.03%
1 week-14.61%
Current month-12.95%
1 month-18.15%
3 months-41.57%
6 months-43.91%
Current year-27.27%
1 week 0.64
Extreme 0.645
0.73
1 month 0.64
Extreme 0.645
0.92
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
76
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 2026-02-04
Director of Finance/CFO - 2020-02-05
Chief Tech/Sci/R&D Officer - 2020-06-10
Director TitleAgeSince
Chairman 56 2026-05-12
Director/Board Member 72 2023-12-31
Director/Board Member 68 2024-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/23/25 Free

Chief Financial Officer

929,208 1.2269%
2/17/25 Buy

Chief Executive Officer

135,000 0.1783%
2/17/25 Sell

Chief Executive Officer

278,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
-3.03%-14.61%-28.51%-88.74% 22.49M
-1.34%-3.09%+56.10%+68.83% 65.45B
+0.59%-1.83%+8.98%+90.01% 58.93B
+0.54%+0.45%+25.96%+87.77% 55.21B
-2.34%-3.90%+10.90%+115.97% 46.1B
+0.09%-6.08%+18.67%+25.90% 42.49B
-2.58%+0.24%+18.54%+41.28% 35.56B
-1.76%-11.56%+126.44%+649.27% 34.57B
-0.17%-1.83%+82.46%+57.69% 32.46B
-1.69%-0.79%-40.58%+382.68% 26.28B
Average -1.17%-4.52%+27.90%+143.07% 40B
Weighted average by Cap. -0.83%-3.29%+34.17%+143.40%

Financials

2026 *2027 *
Net sales 20.6M 2.02M 1.84M 1.71M 1.54M 2.9M 189M 3.01M 8.14M 102M 7.59M 7.43M 322M 28.65M 2.81M 2.57M 2.37M 2.14M 4.03M 263M 4.19M 11.33M 142M 10.55M 10.33M 448M
Net income -90M -8.84M -8.06M -7.45M -6.73M -12.67M -826M -13.16M -35.58M -446M -33.15M -32.46M -1.41B -87.95M -8.64M -7.88M -7.28M -6.57M -12.38M -807M -12.87M -34.77M -436M -32.4M -31.72M -1.38B
Net Debt -80.35M -7.89M -7.2M -6.65M -6M -11.31M -737M -11.75M -31.76M -398M -29.6M -28.98M -1.26B -48M -4.71M -4.3M -3.97M -3.59M -6.75M -440M -7.02M -18.97M -238M -17.68M -17.31M -751M
Projected Income Statement - Annual - Intervacc AB
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
26-11-18 SEK 0.6720 -3.03% 531,531
26-11-17 SEK 0.6930 -5.07% 320,181
26-11-16 SEK 0.7300 +8.31% 965,093
26-11-13 SEK 0.6740 -3.30% 1,399,509
26-11-12 SEK 0.6970 -11.44% 2,215,993
  1. Stock Market
  2. Stocks
  3. IVACC Stock